Recent Updates
Recently added Catalysts

PET scan using florbetapir, MRI Scan

Phase 1

Alzheimer's Disease | Unknown | Neurology |Eli Lilly and Company|Last Updated: Jun 28, 2018

Success Probability
Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
Premium
Market & Valuation
rNPV $3.2B
Market Size $9.4B
Revenue Basis $1.6B
Competitors 6
Premium
Trial Design
UNCONTROLLEDBiomarker
Total Trials1
Total Enrollment56
FDA Designations
No designations recorded
Clinical Trials (1)
NCT IDTitlePhaseStatusEnrollmentVelocityDesignStartCompletionLast UpdatedSitesCountries
NCT01459016A Non-drug Methods Study in Participants With Alzheimer's DiseasePHASE1 COMPLETED 56Dec 1, 2011Dec 1, 2014Jun 28, 201816 France
Unlock Drug Trial Details
Study Endpoints
Primary Endpoints
Change From Baseline in Volumetric Magnetic Resonance Imaging (vMRI) - Brain Boundary Shift Integral (BBSI) and Ventricular Boundary Shift Integral (VBSI)
Baseline, 6 Mos; Baseline, 12 Mos

BBSI and VBSI were calculated based on the voxel-wise difference between co-registered baseline and follow-up scans. Least squares (LS) mean value was controlled for baseline value and visit.

Change From Baseline in Volumetric Magnetic Resonance Imaging (vMRI) - Hippocampus Volume Average Percent (%) Change (Chg)
Baseline, 6 Mos; Baseline, 12 Mos

Automated hippocampal volumetry was performed using the Learning Embeddings for Atlas Propagation (LEAP) algorithm. LS mean value was controlled for baseline value and visit.

Change From Baseline in Resting State Functional Magnetic Resonance Imaging (rsfMRI)
Baseline, 6 Mos; Baseline, 12 Mos

Distributed functional connectivity in selected brain networks was calculated from the rsfMRI scans. Values were derived from low-frequency (0.01-0.1 hertz \[Hz\]) temporal correlations between different regions over the approximately 6-minute rsfMRI time series scan. Distributed measures of functional connectivity were calculated as the mean Pearson correlation between the average low-frequency time courses in predefined sets of regions of interest (ROI) within the default mode network (DMN), salience network (SN) and sensorimotor networks (SMN). LS mean value was controlled for baseline value and visit.

Change From Baseline in Diffusion Tensor Imaging (DTI) Using Fractional Anisotropy (FA)
Baseline, 6 Mos; Baseline, 12 Mos

DTI scans used FA to measure water diffusion directionality in selected white matter (WM) tracts. ROI: Corpus collosum (CC), internal capsule (IC), posterior cingulum bundle (PCB), temporal white matter (TWM), uncinate fasciculus (UF), superior longitudinal fasciculus (SLF). LS mean value was controlled for baseline value and visit.

Change From Baseline in Diffusion Tensor Imaging (DTI) Using Mean Diffusivity (MD)
Baseline, 6 Mos; Baseline, 12 Mos

DTI scans used MD to measure the overall magnitude of water diffusion in selected WM tracts, without specific regard to directionality. ROI: CC, IC, PCB, TWM, UF, SLF. LS mean value was controlled for baseline value and visit.

Secondary Endpoints
Baseline Brain Amyloid Load Using Positron Emission Tomography (PET) and Florbetapir
Baseline
Number of Participants With Vasogenic Edema on MRI Scan at a Field Strength of 3 Tesla (3T)
Baseline
Number of Participants With Microhemorrhage on MRI Scan at a Field Strength of 3T
Baseline, 6 Mos; Baseline, 12 Mos
Unlock Study Endpoints
Study Design & Arms
AllocationNA
MaskingNONE
ModelSINGLE_GROUP
PurposeBASIC_SCIENCE
Treatment Arms
ArmTypeDescription
Imaging BiomarkersEXPERIMENTAL -
Interventions
NameTypeDescription
PET scan using florbetapirOTHERA single intravenous microdose of 260 MBq (7 mCi) 18F-AV-45 (florbetapir F 18) will be administered.
MRI ScanOTHERThree different measurements will be taken: volumetric MRI (vMRI), diffusion tensor imaging (DTI), and resting state functional MRI (rsfMRI). In addition, radiological MRI scans will be taken to monitor vasogenic edema and microhemorrhages.
Unlock Study Design Details
Eligibility Criteria
Age Range55 Years — N/A
SexALL
Healthy VolunteersNo
Study Sites16

Inclusion Criteria: * Present with prodromal Alzheimer's Disease (AD) or mild AD based on the disease diagnostic criteria * Are men or post-menopausal women, at least 55 years of age. Post-menopausal women are defined as women who have had a hysterectomy and/or bilateral oophorectomy; or who have b...

Countries:France
Unlock Eligibility Criteria